HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   Articles of Interest (https://her2support.org/vbulletin/forumdisplay.php?f=31)
-   -   Phenotypic changes of HER2-positive breast cancerduring and after dual HER2 blockade (https://her2support.org/vbulletin/showthread.php?t=69305)

Nguyen 05-03-2021 08:01 AM

Phenotypic changes of HER2-positive breast cancerduring and after dual HER2 blockade
 
Phenotypic changes of HER2-positive breast cancerduring and after dual HER2 blockade


https://www.nature.com/articles/s41467-019-14111-3.pdf

The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highlyaddicted to the HER2 pathway. However,∼20–60% of HER2+/HER2-E tumors do notachieve a complete response following anti-HER2 therapies. Here we evaluate geneexpression data before, during and after neoadjuvant treatment with lapatinib and trastu-zumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines. Ourresults reveal that dual HER2 blockade in HER2-E disease induces a low-proliferative LuminalA phenotype both in patient’s tumors and in vitro models. These biological changes are moreevident in hormone receptor-positive (HR+) disease compared to HR-negative disease.Interestingly, increasing the luminal phenotype with anti-HER2 therapy increased sensitivityto CDK4/6 inhibition. Finally, discontinuation of HER2-targeted therapy in vitro, or acquiredresistance to anti-HER2 therapy, leads to restoration of the original HER2-E phenotype. Ourfindings support the use of maintenance anti-HER2 therapy and the therapeutic exploitationof subtype switching with CDK4/6 inhibition


All times are GMT -7. The time now is 07:40 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2021, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021